Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 11 March 2013 | By Alexander Gaffney, RAC,
China's State Food and Drug Administration (SFDA) will soon be revamped and given additional authority under a planned governmental reorganization that will see various regulatory oversight agencies consolidated under its authority, reports various news outlets.
News of the reorganization broke last week in a report by the South China Morning Post, which wrote that the National People's Congress (NPC)-the last under outgoing Prime Minister Wen Jiabao-was considering changes in the wake of numerous quality scandals involving food and drug products.
One scandal in particular, as reported by Pharmalot'sEd Silverman last year, was the case of so-called "gutter oil"-recycled cooking oil-used in the manufacture of antibiotics in the country instead of the proper soybean oil used to make 7-aminophalosporinic acid (7-ACA).
The larger issue, the SCMP wrote, is that right now regulatory authority in the country is highly fragmented as the result of political struggles and scandals.
"When founded in 2003, [SFDA] was a ministerial-level agency directly under the State Council and meant to have greater power," SCMPwrote. "But it was downgraded and affiliated to the Ministry of Health in 2008 after a series of corruption scandals involving several SFDA officials. These included its head, Zheng Xiaoyu , who was convicted and executed for taking bribes and dereliction of duty."
In the meantime, however, further scandals have continued to erupt, threatening not only Chinese consumers, but consumers abroad as well. The 2008 heparin scandal in the US, in which contaminated supplies thought to have originated in China made their way into the US, killing more than 80 people, is a prime example of the latter.
"Consumer confidence in the mainland's food and drug industry has been shattered," SCMP noted.
Now, in a bid to restore that confidence, the NPC is moving to consolidate power in a newly-endowed SFDA. Under the new plans, China Daily reports that SFDA would be elevated to a ministerial-level agency. The changes would mostly affect food regulation in the country, with the State Council's Food Safety Office, the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) and the State Administration for Industry and Commerce (SAIC)-and their staff-all coming under SFDA.
But if the agency's food authority got a massive boost, reports don't mention any changes to the way SFDA regulates pharmaceutical or medical device products-something mentioned as possible by the SCMP last week when they noted the NPC could focus solely on the regulation of food products.
However, the additional authority gained by the agency by way of its promotion within China's government to a ministerial agency could boost its ability to argue for additional resources and authority to go after counterfeiters and other quality concerns that have plagued the country as of late. A boost in its regulatory capacity would be a welcome change for industry, which has long complained about the agency's lengthy and sometimes confusing regulatory processes.
Tags: Reorganization, SFDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.